JN
Therapeutic Areas
Cloudbreak Pharmaceutical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CBT-001 | Pterygium (and Pinguecula) | Phase 3 |
| Undisclosed Program (MGD) | Meibomian Gland Dysfunction | Pre-clinical / Clinical |
| Undisclosed Program (GFS) | Glaucoma Filtration Surgery | Pre-clinical / Clinical |
| Undisclosed Program (Adjunct GFS) | Adjunct Therapy for Glaucoma Filtration Surgery | Pre-clinical / Clinical |
| Undisclosed Program (AMD) | Age-Related Macular Degeneration | Pre-clinical / Clinical |
| Undisclosed Program (DR) | Diabetic Retinopathy | Pre-clinical / Clinical |
Leadership Team at Cloudbreak Pharmaceutical
VD
Van Dinh, MBA
Chief Operating Officer
RY
Rong Yang, Ph.D.
Chief Scientific Officer
AA
Abu Abraham, M.D.
Chief Medical Officer
MR
Michael Rowe, M.Sc.
Chief Business Officer
GB
Greg Brooks, B.Sc.
Chief Commercial Officer
EC
Elizabeth Capan, J.D.
Chief Patent Officer
WK
W. Ken Fang, Ph.D.
Chief Innovation Officer
SW
Scott Whitcup, M.D.
Scientific Advisory Board
JH
John Hovanesian, M.D.
Scientific Advisory Board